Clinical Trial Search

Primary: Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36 — -80.5; -79.1; -83.3; 2.3 Percentage — p=<0.0001

Primary: Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy — 176; 117 Participants

Primary: Self-reported Stress — 1.89; 1.87; 1.59; 1.68 score on a scale

Primary: Progression-free Survival. — 0; 0; 1 Participants

Primary: Average Number of Heavy Drinking Days — 15.1; 15.9; 13.2; 11.3 days

Primary: Number of Adverse Events (Phase Ib) — 10; 2; 2; 1 Number of Events

Primary: Sustained Virological Response (SVR) — 17; 10; 56; 83 Participants — p=0.008

Primary: Scale of Adherence to Antihypertensive Drug Treatment — 9.31; 9.51; 7.86; 9.23 score on a scale

Primary: Number of Colony Forming Units Per Millilitre — 80300000; 79900000; 74000000; 73000000 CFU/ml

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0; 0; 127; 43 Participants

Primary: Intervention Satisfaction: Satisfaction With Therapy and Therapist Scale-Revised (STTS-R) — 26.71; 27.33; 28.86; 27.75 scores on a scale — p=0.519

Primary: Total Opioid Dose (MME) Used in 24 Hours — 103.61; 109.17 total morphine milligram equivalents — p=0.3938

Primary: Change in Depression Symptom Control as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System) — -4.3; -4.0 T-score — p=0.677

Primary: Proportion of Participants Filling a Prescription for PrEP — 0; 2; 2; 5 Participants

Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…